Leqembi is expensive out of pocket, with costs cited as high as $26,500 per year. However, you don’t need to pay as much under Medicare. Afterward, it pays for 80% of the cost. So, once you meet ...

Biogen raised annual profit forecast and beat third-quarter profit expectations on Wednesday, as its cost-cutting measures ...

Why it matters: The findings, published Monday in JAMA Internal Medicine, add to questions around the coverage of Leqembi, an infusable $26,500-a-year ... lecanemab could cost taxpayers between ...

Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi ... but still well below the $26,500 set by Eisai after it was approved ...

The company maintains that Leqembi's wholesale acquisition cost of $26,500 delivers a projected societal value of $37,600 and that over 10 years "could bring potential positive social impact of ...

Even CMS’s projected cost to Medicare of $550 million for Leqembi in 2024 appears to be off base. There were several explicitly stated assumptions made by CMS in its recent assessment of the ...

Both treatments require careful monitoring of patients, it said. Leqembi costs $26,500 annually in the U.S. Lilly's drug is also under review by the European health regulators, which rejected ...